Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
PROGYNY, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 33.99 USD | +0.32% | +0.65% | +9.12% | |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
Financials (USD)
| Sales 2023 * | 1,092 M | Sales 2024 * | 1,311 M | Capitalization | 3,257 M |
|---|---|---|---|---|---|
| Net income 2023 * | 58.00 M | Net income 2024 * | 72.00 M | EV / Sales 2023 * | 2,75x |
| Net cash position 2023 * | 254 M | Net cash position 2024 * | 422 M | EV / Sales 2024 * | 2,16x |
| P/E ratio 2023 * | 58,6x | P/E ratio 2024 * | 48,1x | Employees | 397 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 91.99% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.32% | ||
| 1 week | +0.65% | ||
| Current month | +10.14% | ||
| 1 month | +11.48% | ||
| 3 months | -10.03% | ||
| 6 months | -9.09% | ||
| Current year | +9.12% |
1 week
33.50
34.74
1 month
29.4434.74
Current year
28.0344.95
1 year
28.0344.95
3 years
25.6768.32
5 years
13.2968.32
10 years
13.2968.32
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Anevski
CEO | Chief Executive Officer | 55 | 2016 |
Michael Sturmer
PSD | President | 46 | 2021 |
Mark Livingstone
DFI | Director of Finance/CFO | 57 | 2019 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 66 | 2010 |
Kevin Gordon
BRD | Director/Board Member | 60 | 2019 |
Norman Payson
BRD | Director/Board Member | 74 | 2016 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.22% | 1 M€ | -13.95% | ||
| 2.85% | 131 M€ | +15.18% | ||
| 2.50% | 5 M€ | +7.07% | - | |
| 1.94% | 9 M€ | 0.00% | - | |
| 1.84% | 80 M€ | -0.70% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-29 | 33.99 | +0.32% | 498,122 |
| 23-11-28 | 33.88 | -0.88% | 715,917 |
| 23-11-27 | 34.18 | -0.87% | 731,625 |
| 23-11-24 | 34.48 | +2.10% | 387,917 |
| 23-11-22 | 33.77 | +2.77% | 793,625 |
Delayed Quote Nasdaq, November 29, 2023 at 04:00 pm EST
More quotes
Progyny, Inc. is a fertility benefits management company. The Company specializes in fertility and family-building benefits solutions in the United States. The Company provides its benefit through its Smart Cycle approach. The Smart Cycles include medical services required for a member's full course of treatment, including all necessary diagnostic testing and access to the technology. In addition, to its fertility benefits solution, it offers an integrated pharmacy benefits solution, Progyny Rx, which is added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. As part of this solution, the Company provides care management services, which include its formulary plan design, simplified authorization, assistance with prescription fulfillment and timely delivery of the medications by its network of specialty pharmacies, as well as medication administration training, pharmacy support services and patient care advocates.
Sector
Managed Healthcare
Calendar
2024-02-25
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
33.99USD
Average target price
46.25USD
Spread / Average Target
+36.07%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +9.12% | 3 257 M $ | |
| +0.91% | 495 B $ | |
| -9.28% | 109 B $ | |
| -5.81% | 59 390 M $ | |
| -14.06% | 37 650 M $ | |
| +6.24% | 20 453 M $ | |
| -36.05% | 1 422 M $ | |
| -0.13% | 453 M $ |